|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1991-4-5
|
|
pubmed:abstractText |
Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-2425961,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-2521264,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-2673478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-2889118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-2934462,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-3046382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-3052137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-3052139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-3318448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-3651725,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-4164775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-6065984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-6141581,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-6146753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-6731799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2292704-7046363
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-3050
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1096-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2292704-Administration, Oral,
pubmed-meshheading:2292704-Adult,
pubmed-meshheading:2292704-Alzheimer Disease,
pubmed-meshheading:2292704-Blood-Brain Barrier,
pubmed-meshheading:2292704-Depressive Disorder,
pubmed-meshheading:2292704-Double-Blind Method,
pubmed-meshheading:2292704-Female,
pubmed-meshheading:2292704-Humans,
pubmed-meshheading:2292704-Injections, Intravenous,
pubmed-meshheading:2292704-Male,
pubmed-meshheading:2292704-Middle Aged,
pubmed-meshheading:2292704-S-Adenosylmethionine
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.
|
|
pubmed:affiliation |
Department of Neurology, King's College Hospital, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
